All trading involves risk. Contracts for Difference (CFDs) are complex instruments and may not be suitable for all investors. Please refer to Risk Disclosure and Risk Fact Sheet on Capital.com/en-sg.
Open platformOpen platform

Oncology firm Delcath Systems' Q3 revenue beats on Hepzato growth 

By Reuters News


Overview

  • US interventional oncology firm's Q3 revenue rose sharply, beating analyst expectations

  • Adjusted EBITDA more than doubled from prior year

  • Company raised 2026 revenue guidance to $115-117 mln


Outlook

  • Delcath Systems raises 2026 revenue guidance to $115 mln-$117 mln

  • Company expects 2026 gross margin between 87% and 89%

  • Delcath Systems anticipates positive adjusted EBITDA for full-year 2026


Result Drivers

  • HEPZATO KIT GROWTH - Q3 revenue growth driven by 72% increase in HEPZATO KIT volume year over year

  • TREATMENT CENTER EXPANSION - Company attributed growth to increased number and engagement of active treatment centers

  • MARGIN IMPROVEMENT - Gross margin rose to 89% from 87% in prior year, contributing to higher profitability


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$35.1 mln

$26.03 mln (6 Analysts)

Q3 Net Income

$6.95 mln

Q3 Gross Profit

$31.18 mln

Q3 Operating Expenses

$24.07 mln

Q3 Operating Income

$7.12 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Delcath Systems Inc is $24.00, about 60.8% above its November 6 closing price of $14.93


Reuters Recommended Reads

  • Nov 8 - RadNet beats Q3 adjusted EPS estimates, lifts 2026 outlook

  • Nov 9 - ADC Therapeutics Q3 revenue beats estimates on sales volume

  • Nov 9 - Zura Bio's skin disease drug fails mid-stage trial


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.